Market Closed -
Nasdaq
16:30:00 2024-05-10 EDT
|
5-day change
|
1st Jan Change
|
2.118
USD
|
-9.86%
|
|
-7.90%
|
-18.21%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5.497
|
3.81
|
30.5
|
52.64
|
16.86
|
15.37
|
Enterprise Value (EV)
1 |
2.78
|
2.862
|
2.987
|
-30.82
|
-24.7
|
2.44
|
P/E ratio
|
3.06
x
|
-0.79
x
|
-1.99
x
|
-6.74
x
|
-0.67
x
|
-0.59
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
196
x
|
423
x
|
-
|
-
|
-
|
7.54
x
|
EV / Revenue
|
99.3
x
|
318
x
|
-
|
-
|
-
|
1.2
x
|
EV / EBITDA
|
-0.92
x
|
-0.67
x
|
-
|
-
|
-
|
-0.11
x
|
EV / FCF
|
-1.12
x
|
-0.72
x
|
-0.55
x
|
2.33
x
|
2.57
x
|
-0.17
x
|
FCF Yield
|
-89.3%
|
-139%
|
-180%
|
42.9%
|
38.9%
|
-590%
|
Price to Book
|
0.45
x
|
0.6
x
|
1.03
x
|
0.52
x
|
0.22
x
|
0.29
x
|
Nbr of stocks (in thousands)
|
118
|
170
|
2,054
|
5,275
|
5,140
|
5,935
|
Reference price
2 |
46.49
|
22.44
|
14.85
|
9.979
|
3.280
|
2.590
|
Announcement Date
|
19-03-12
|
20-02-03
|
21-03-25
|
22-03-28
|
23-03-31
|
24-04-01
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.028
|
0.009
|
-
|
-
|
-
|
2.039
|
EBITDA
1 |
-3.028
|
-4.242
|
-
|
-
|
-
|
-21.41
|
EBIT
1 |
-4.471
|
-5.685
|
-6.546
|
-9.441
|
-14.35
|
-21.5
|
Operating Margin
|
-15,967.86%
|
-63,166.67%
|
-
|
-
|
-
|
-1,054.24%
|
Earnings before Tax (EBT)
1 |
1.727
|
-4.183
|
-12.34
|
-7.171
|
-22.11
|
-22.88
|
Net income
1 |
1.727
|
-4.183
|
-12.34
|
-7.171
|
-22.11
|
-22.88
|
Net margin
|
6,167.86%
|
-46,477.78%
|
-
|
-
|
-
|
-1,122.22%
|
EPS
2 |
15.17
|
-28.39
|
-7.471
|
-1.479
|
-4.915
|
-4.376
|
Free Cash Flow
1 |
-2.482
|
-3.98
|
-5.383
|
-13.23
|
-9.594
|
-14.39
|
FCF margin
|
-8,865.62%
|
-44,223.61%
|
-
|
-
|
-
|
-705.59%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-03-12
|
20-02-03
|
21-03-25
|
22-03-28
|
23-03-31
|
24-04-01
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1.779
|
-2.585
|
-3.803
|
-2.298
|
-5.101
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.047
|
-1.81
|
-3.535
|
-5.077
|
-6.239
|
Net income
1 |
-0.047
|
-1.81
|
-6.544
|
-6.177
|
-6.239
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-0.3400
|
-1.190
|
-1.180
|
-1.170
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-10
|
22-03-28
|
22-05-16
|
22-08-12
|
22-11-10
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2.72
|
0.95
|
27.5
|
83.5
|
41.6
|
12.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-2.48
|
-3.98
|
-5.38
|
-13.2
|
-9.59
|
-14.4
|
ROE (net income / shareholders' equity)
|
21.3%
|
-37%
|
-61.5%
|
-10.9%
|
-25.2%
|
-36.1%
|
ROA (Net income/ Total Assets)
|
-25.1%
|
-29%
|
-19.6%
|
-8.86%
|
-10%
|
-20.1%
|
Assets
1 |
-6.867
|
14.44
|
62.99
|
80.91
|
220.5
|
113.9
|
Book Value Per Share
2 |
102.0
|
37.10
|
14.40
|
19.30
|
14.70
|
8.920
|
Cash Flow per Share
2 |
0.1400
|
0.3200
|
1.320
|
12.40
|
6.610
|
0.4800
|
Capex
1 |
0.04
|
-
|
-
|
-
|
-
|
0.43
|
Capex / Sales
|
128.57%
|
-
|
-
|
-
|
-
|
20.94%
|
Announcement Date
|
19-03-12
|
20-02-03
|
21-03-25
|
22-03-28
|
23-03-31
|
24-04-01
|
|
1st Jan change
|
Capi.
|
---|
| -18.21% | 12.57M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|